Literature DB >> 11183902

Economic considerations in overactive bladder.

T W Hu, T H Wagner.   

Abstract

Many costs are associated with overactive bladder (OAB). They include direct costs, such as those associated with treatment, diagnosis, routine care, and the consequences of the disease; indirect costs of lost wages and productivity; and intangible costs associated with pain, suffering, and decreased quality of life. Quantification of all these costs is essential for establishing the total economic burden of a disease on society. Currently, the total economic burden of OAB is unknown. However, various studies have determined that the economic burden of urinary incontinence, one of the symptoms of OAB, is substantial. It is also important to establish the economic impact of various interventions for OAB. Cost-minimization, cost-outcome, cost-utility, and cost-benefit models can be used for these analyses. The most difficult aspect of evaluating the economic impact of a treatment is estimating the intangible costs.

Entities:  

Mesh:

Year:  2000        PMID: 11183902

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  12 in total

1.  Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.

Authors:  Rujin Ju; Joanne Garrett; Jennifer M Wu
Journal:  Int Urogynecol J       Date:  2013-10-25       Impact factor: 2.894

2.  Clinical impact of overactive bladder.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2002

3.  Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E(2) Instillation.

Authors:  Jun Hyung Oh; Yong Seok Lee; Long Hu Jin; Yong Hyun Kwon; Won Hee Park; Tack Lee
Journal:  Korean J Urol       Date:  2010-01-21

4.  [Overactive bladder--which diagnosis investigations are necessary before initiating primary treatment?].

Authors:  B Schönberger
Journal:  Urologe A       Date:  2003-04-25       Impact factor: 0.639

5.  Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

Authors:  D Getsios; J J Caro; K J Ishak; W El-Hadi; K Payne; M O'connel; D Albrecht; W Feng; D Dubois
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  Conservative therapy for overactive bladder: pelvic floor exercises.

Authors:  Christina Kwon; Peter K Sand
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

7.  Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2021-05-13       Impact factor: 2.705

Review 8.  Social, economic, and health utility considerations in the treatment of overactive bladder.

Authors:  Emilio Sacco; Daniele Tienforti; Alessandro D'Addessi; Francesco Pinto; Marco Racioppi; Angelo Totaro; Daniele D'Agostino; Francesco Marangi; Pierfrancesco Bassi
Journal:  Open Access J Urol       Date:  2010-02-11

Review 9.  Oxybutynin topical gel in the treatment of overactive bladder.

Authors:  G Willy Davila
Journal:  Open Access J Urol       Date:  2010-06-16

Review 10.  Emerging treatments for overactive bladder: clinical potential of botulinum toxins.

Authors:  Douglas G Tincello; Tina Rashid; Vladimir Revicky
Journal:  Res Rep Urol       Date:  2014-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.